J Blay

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. pmc Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy
    I Ray-Coquard
    Centre L Bérand, Lyon, France
    Br J Cancer 88:181-6. 2003
  2. pmc Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
    A Dufresne
    Department of Medical Oncology and Department of Pathological Anatomy, Hospital Edouard Herrriot, Lyon, France
    Br J Cancer 103:482-5. 2010
  3. doi request reprint Trabectedin's contribution to the treatment of sarcomas
    Jean Yves Blay
    Department of Medical Oncology, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Expert Rev Anticancer Ther 13:3-9. 2013
  4. pmc Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer
    Philippe A Cassier
    Department of Medecine, Centre Leon Berard, Lyon, France
    BMC Cancer 11:213. 2011
  5. pmc Validation of prognostic scores for survival in cancer patients beyond first-line therapy
    Olivier Tredan
    Universite de Lyon, Centre Leon Berard, Department of Medical Oncology, 28 rue Laennec, 69008 Lyon, France
    BMC Cancer 11:95. 2011
  6. pmc Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
    Aurore Blesius
    Department of Medicine, Institut Roussy, Villejuif, France
    BMC Cancer 11:72. 2011
  7. pmc CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways
    Nathalie Voorzanger-Rousselot
    Equipe Cytokines et Cancer, Unité INSERM U590, Centre Leon Berard, 28 rue Laennec, 69373 Lyon Cedex 08, France
    BMC Cancer 6:75. 2006
  8. pmc Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region
    Antoine Lurkin
    Centre Leon Berard, Lyon, France
    BMC Cancer 10:150. 2010
  9. pmc Impact of organised programs on colorectal cancer screening
    Francois Eisinger
    Paoli Calmettes Institute INSERM UMR599 232 Bd, St Marguerite, 13009 Marseille, France
    BMC Cancer 8:104. 2008
  10. doi request reprint A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST
    Jean Yves Blay
    Centre Leon Berard, Lyon, France
    Cancer Treat Rev 37:373-84. 2011

Detail Information

Publications146 found, 100 shown here

  1. pmc Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy
    I Ray-Coquard
    Centre L Bérand, Lyon, France
    Br J Cancer 88:181-6. 2003
    ..The 'day 1' model identifies a small population of patients at high risk for FN, but has a lower sensitivity than the day 5 model...
  2. pmc Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
    A Dufresne
    Department of Medical Oncology and Department of Pathological Anatomy, Hospital Edouard Herrriot, Lyon, France
    Br J Cancer 103:482-5. 2010
    ..Imatinib induces responses and disease stabilisations in non-resectable patients with aggressive fibromatosis (AF). The precise target of imatinib in AF and predictive factors for response to treatment are unknown...
  3. doi request reprint Trabectedin's contribution to the treatment of sarcomas
    Jean Yves Blay
    Department of Medical Oncology, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France
    Expert Rev Anticancer Ther 13:3-9. 2013
    ..Numerous clinical studies currently underway with trabectedin are aiming to resolve a variety of questions in order to optimize its use in clinical practice...
  4. pmc Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer
    Philippe A Cassier
    Department of Medecine, Centre Leon Berard, Lyon, France
    BMC Cancer 11:213. 2011
    ..Chemokines CCL19, CCL20 and CCL21 and their receptors CCR6 and CCR7, were assessed as potential biomarkers of metastatic dissemination in primary breast cancer...
  5. pmc Validation of prognostic scores for survival in cancer patients beyond first-line therapy
    Olivier Tredan
    Universite de Lyon, Centre Leon Berard, Department of Medical Oncology, 28 rue Laennec, 69008 Lyon, France
    BMC Cancer 11:95. 2011
    ..We aimed to validate prognostic scores for survival in patients undergoing chemotherapy for advanced or metastatic cancer after first-line treatment...
  6. pmc Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
    Aurore Blesius
    Department of Medicine, Institut Roussy, Villejuif, France
    BMC Cancer 11:72. 2011
    ..We analyzed the outcome of patients with non metastatic locally advanced primary GIST treated with IM within the prospective BFR14 phase III trial...
  7. pmc CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways
    Nathalie Voorzanger-Rousselot
    Equipe Cytokines et Cancer, Unité INSERM U590, Centre Leon Berard, 28 rue Laennec, 69373 Lyon Cedex 08, France
    BMC Cancer 6:75. 2006
    ..CD40L was found to reduce doxorubicin-induced apoptosis in non Hodgkin's lymphoma cell lines through caspase-3 dependent mechanism. Whether this represents a general mechanism for other tumor types is unknown...
  8. pmc Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region
    Antoine Lurkin
    Centre Leon Berard, Lyon, France
    BMC Cancer 10:150. 2010
    ..We prospectively assessed the medical management of all patients diagnosed with sarcoma in a European region over a one-year period to identify the quantity of first diagnosis compared to central expert review (CER)...
  9. pmc Impact of organised programs on colorectal cancer screening
    Francois Eisinger
    Paoli Calmettes Institute INSERM UMR599 232 Bd, St Marguerite, 13009 Marseille, France
    BMC Cancer 8:104. 2008
    ..Colorectal cancer (CRC) screening has been shown to decrease CRC mortality. Organised mass screening programs are being implemented in France. Its perception in the general population and by general practitioners is not well known...
  10. doi request reprint A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST
    Jean Yves Blay
    Centre Leon Berard, Lyon, France
    Cancer Treat Rev 37:373-84. 2011
    ..Following progression on these agents, patients have limited treatment options. This critical unmet need is being addressed by the development of new TKIs and the use of novel regimens with approved agents...
  11. doi request reprint Updating progress in sarcoma therapy with mTOR inhibitors
    J Y Blay
    Department of Medical Oncology, Centre Leon Berard, Lyon, France
    Ann Oncol 22:280-7. 2011
    ..The mammalian target of rapamycin (mTOR) pathway has been identified as a therapeutic target in many sarcomas and this article reviews the role of this pathway and updates clinical data for the available mTOR inhibitors...
  12. pmc Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors
    Jean Yves Blay
    Leon Berard Center, Claude Bernard University, Lyon, France
    Cancer 116:5126-37. 2010
    ..In addition, areas of consensus and points of divergence among the guidelines are highlighted along with any unresolved issues...
  13. doi request reprint Adjuvant chemotherapy in localized soft tissue sarcomas: still not proven
    Jean Yves Blay
    Centre Leon Berard, Medical Oncology Department, 28 rue Laennec, 69008 Lyon, France
    Oncologist 14:1013-20. 2009
    ..We conclude that adjuvant chemotherapy has not been proven to improve the outcome of an unselected population of patients. Several hypotheses are proposed to account for this observation...
  14. doi request reprint Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib
    J Y Blay
    Léon Bérard Comprehensive Cancer Centre, Universite Claude Bernard Lyon I, Lyon, France
    Ann Oncol 21:208-15. 2010
    ....
  15. ncbi request reprint [Neoadjuvant chemotherapy in sarcoma]
    Jean Yves Blay
    Hôpital Edouard Herriot et Unité Inserm U590, Centre Leon Berard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 93:1093-8. 2006
    ..In elderly and/or frail patients, conversely, single agent doxorubicin may be the preferred option...
  16. ncbi request reprint [Targeted therapies of cancer: not lost in translation]
    Jean Yves Blay
    Hopital Edouard Herriot, Oncologie Médicale, Pavillon E, 5, Place d Arsonval, 69437 Lyon Cedex
    Bull Cancer 93:799-804. 2006
    ..These observations point out the need to introduce translational research as a key element to schedule and evaluate the activity of novel targeted agents in the clinics...
  17. ncbi request reprint Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group
    Jean Yves Blay
    Unité INSERM U590 Centre Léon Bérard and Université Claude Bernard Lyon I and Hopital Edouard Herriot, Lyon, France
    J Clin Oncol 25:1107-13. 2007
    ..Imatinib is the standard treatment of advanced GI stromal tumors (GISTs). It is not known whether imatinib may be stopped in patients in whom disease is controlled...
  18. ncbi request reprint Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE)
    Jean Yves Blay
    Hopital Edouard Herriot, Oncologie Médicale, Pavillon E, 5 Place d Arsonval, 69437 Lyon Cedex 03, France
    Crit Rev Oncol Hematol 64:106-14. 2007
    ....
  19. pmc Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma
    Jean Yves Blay
    CONTICANET and UJOMM Hôpital Edouard Herrot, Centre Leon Berard, Lyon, France
    Clin Cancer Res 14:6656-62. 2008
    ....
  20. doi request reprint [Edifice program: analysis of screening exam practices for cancer in France]
    J Y Blay
    INSERM U590, Centre Leon Berard, UJOMM HEH and Conticanet FP6 018806, 69373 Lyon, France
    Bull Cancer 95:1067-73. 2008
    ..The objectives of the Edifice study were to analyze a large cohort of patients and doctors in order to further characterize these parameters...
  21. doi request reprint New paradigms in gastrointestinal stromal tumour management
    J Y Blay
    Cytokine and Cancer Unit, Léon Bérard Cancer Centre, Lyon, France
    Ann Oncol 20:i18-24. 2009
    ..Many patients exhibit intolerance or resistance to first-line therapy with imatinib mesylate. Sunitinib malate is approved multinationally for the treatment of advanced imatinib-refractory GIST...
  22. ncbi request reprint Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO
    J Y Blay
    Unité Inserm 590, Centre Leon Berard, 69008 Lyon and Hopital Edouard Herriot, Place d Arsonval, 69003 Lyon, France
    Ann Oncol 16:566-78. 2005
    ..The objectives of this international consensus meeting were to describe the optimal management procedures for patients with GIST in localized and advanced stages, as well as research issues for the future...
  23. doi request reprint Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumour?
    Jean Yves Blay
    Département de Médecine and Unité INSERM U590, Centre Leon Berard, Lyon, France
    Curr Opin Oncol 21:360-6. 2009
    ..In this setting, the optimal duration of treatment is not known, and it is generally considered that treatment should be given until progression or intolerance...
  24. doi request reprint Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations
    Jean Yves Blay
    Cytokine and Cancer Unit, Léon Bérard Cancer Centre, 28 rue Laennec, 69008 Lyon, France
    Expert Rev Anticancer Ther 9:831-8. 2009
    ..This article reviews the evidence underlying the updates to the ESMO recommendations on the management of GIST and discusses the implications of the changes...
  25. ncbi request reprint High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults
    J Y Blay
    Centre Léon Bérard and Hôpital Edouard Herriot, Lyon, France
    J Clin Oncol 18:3643-50. 2000
    ..The role of high-dose chemotherapy (HDCT) with hematopoietic stem-cell support in this disease is not established...
  26. ncbi request reprint Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma
    J Y Blay
    Unite Cytokine et Cancer et Département de Médecine, Centre Leon Berard, Lyon, France
    Int J Cancer 72:424-30. 1997
    ....
  27. ncbi request reprint High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series
    J Y Blay
    Centre Leon Berard, Lyon, France
    J Clin Oncol 16:864-71. 1998
    ..The impact of treatment options on survival and late neurologic toxicity was investigated in a series of patients with primary cerebral lymphoma (PCL) and no known cause of immunosuppression...
  28. ncbi request reprint A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy
    J Y Blay
    Centre L BERARD, Lyon, France
    Blood 92:405-10. 1998
    ..1) from those calculated in the model. This risk index could be useful to identify patients at high risk for chemotherapy-induced thrombocytopenia requiring platelet transfusions...
  29. ncbi request reprint The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group
    J Blay
    PARMA Cooperative Group with Fédération Nationale des Centres de Lutte Contre le Cancer FNCLCC, Dutch Haemato Oncology Working Party HOVON, European Organization for Research and Treatment of Cancer EORTC, Lyon, France
    Blood 92:3562-8. 1998
    ....
  30. ncbi request reprint Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens
    J Y Blay
    EORTC Soft Tissue and Bone Sarcoma Group, Brussels, Belgium
    Anticancer Drugs 10:873-7. 1999
    ..Only one patient experienced febrile neutropenia. Raltitrexed as monotherapy is not an effective treatment for patients with ASTS who failed conventional chemotherapy with doxorubicin and ifosfamide...
  31. ncbi request reprint Primary cerebral lymphomas: unsolved issues regarding first-line treatment, follow-up, late neurological toxicity and treatment of relapses. The FNCLCC. French Fédération Nationale des Centres de Lutte contre le Cancer
    J Y Blay
    Centre Leon Berard, Lyon, France
    Ann Oncol 11:39-44. 2000
    ..Primary cerebral non-Hodgkin's lymphomas (NHL) in immunocompetent patients (PCL) are located exclusively in the central nervous system, the eye, or meninges. Clinical management of these patients remains controversial...
  32. ncbi request reprint Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy
    J Y Blay
    Hospices Civils de Lyon and Ctr L Bérard, Lyon, France
    Eur J Cancer 39:64-9. 2003
    ..Long-term survivors are observed in all prognostic subgroups of patients, in particular those achieving a CR to first-line chemotherapy...
  33. ncbi request reprint Time to secondary resistance (TSR) after interruption of imatinib (IM) in advanced GIST: Updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival
    A Le Cesne
    Institut Gustave Roussy, Villejuif, France Centre Leon Berard, Lyon, France Institut Bergonié, Bordeaux, France Centre Oscar Lambret, Lille, France Centre Alexis Vautrin, Nancy, France Institut Paoli Calmettes, Marseille, France La Timone University Hospital, Marseille, France Centre Val d Aurelle, Montpellier, France Institut Claudius Regaud, Toulouse, France Centre René Gauducheau, Nantes, France
    J Clin Oncol 29:10015. 2011
    ..The impact of IM interruption on secondary resistance and overall survival (OS) with longer-term follow-up was unclear...
  34. ncbi request reprint PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072)
    W T van der Graaf
    Radboud University Medical Centre, Nijmegen, Netherlands Centre Léon Bérard, Lyon, France Sarcoma Oncology Center, Santa Monica, CA Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea Institut Bergonié, Bordeaux, France Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo, Italy University of Pennsylvania, Philadelphia, PA National Cancer Center Hospital, Tokyo, Japan Institut Gustave Roussy, Villejuif, France Department of Clinical Oncology, Leiden University Medical Center, Leiden, Netherlands The Royal Marsden NHS Foundation Trust, London, United Kingdom Osaka Medical Center, Osaka, Japan European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium EORTC Headquarters, Brussels, Belgium GlaxoSmithKline Oncology, Uxbridge, United Kingdom GlaxoSmithKline R and D, Greenford, United Kingdom Azienda ULSS 9 Treviso, Department of Medicine
    J Clin Oncol 29:LBA10002. 2011
    ..The efficacy and safety of pazopanib versus placebo as second or later line treatment were evaluated in pts with metastatic STS in a multi-center, international, double-blind, placebo-controlled phase III trial...
  35. ncbi request reprint Neoadjuvant imatinib in patients with locally advanced GIST in the prospective BFR14 trial
    P A Cassier
    Hopital Edouard Herriot, Lyon, France Hôpital de la Timone, Marseille, France Centre Leon Berard, Lyon, France Centre Oscar Lambret, Lille, France Institut Bergonié, Bordeaux, France Institut Paoli Calmette, Marseille, France Centre Alexis Vautrin, Nancy, France Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:10551. 2009
    ..We sought to assess the outcome of patients with locally advanced primary GIST tumors without metastases treated with IM in the neoadjuvant setting within the prospective BFR14 phase III trial...
  36. ncbi request reprint Influence of imatinib interruption and imatinib rechallenge on the residual tumor volume in patients with advanced GIST: Results of the BFR14 prospective French Sarcoma Group randomized phase III trial
    J Domont
    Institut Gustave Roussy, Villejuif, France Centre Leon Berard, Lyon, France Institut Bergonié, Bordeaux, France Centre Oscar Lambret, Lille, France Centre Alexis Vautrin, Nancy, France Institut Paoli Calmettes, Marseille, France La Timone University Hospital, Marseille, France Centre Val d Aurelle, Montpellier, France Institut Claudius Regaud, Toulouse, France Centre René Gauducheau, Nantes, France
    J Clin Oncol 29:10054. 2011
    ..However, the tumor volume of residual lesions at the time of IM interruption and at the time of the best response when IM was reintroduced could influence the long term OS...
  37. ncbi request reprint Trends in screening for colorectal cancer in France
    J Viguier
    CHRU Trousseau, Tours, France Capio Clinique du Parc, Toulouse, France Roche, Bale, Switzerland CHU Besançon, Besancon, France Hôpital Avicenne, Bobigny, France Hôpital Edouard Herriot, Lyon, France Clinique de la Porte de Saint Cloud, Boulogne Billancourt, France Roche, Neuilly sur Seine, France Institut Paoli Calmettes, Marseille, France
    J Clin Oncol 27:1538. 2009
    ..The EDIFICE 2 survey was conducted in 2008, 3 years after EDIFICE 1, to provide a better understanding of French people's participation in colorectal screening programs and to assess the evolution between the two periods...
  38. ncbi request reprint Masatinib mesylate in imatinib-naive locally advanced or metastatic gastrointestinal stromal tumor (GIST): Results of the French Sarcoma Group phase II trial
    A Le Cesne
    Institut Gustave Roussy, Villejuif, France Centre Leon Berard, Lyon, France Institut Bergonié, Bordeaux, France Hopital Robert Debré, Reims, France Centre Oscar Lambret, Lille, France AB Science, Paris, France Hôpital Necker, Paris, France
    J Clin Oncol 27:10507. 2009
    ..Masatinib also inhibits PDGFR and FGFR3. This multicenter phase II study evaluated the efficacy and safety of masatinib as a first-line treatment of advanced GIST...
  39. ncbi request reprint Advanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survival
    M Toulmonde
    Institut Bergonie, Bordeaux, France Centre Oscar Lambret, Lille, France Institut Gustave Roussy, Villejuif, France Centre Georges François Leclerc, Dijon, France Centre René Gauducheau, Nantes, France La Timone University Hospital, Marseille, France Memorial Sloan Kettering Cancer Center, New York, NY Centre Léon Bérard, Lyon, France
    J Clin Oncol 29:10071. 2011
    ..10071 Background: Data regarding the role of systemic therapy in patients (pts) with advanced well-differentiated/dedifferentiated liposarcomas (WLPS/DDLPS) are limited...
  40. ncbi request reprint Trabectedin for advanced sarcomas failing doxorubicin: Analysis of 189 unreported patients in a compassionate use program
    J Blay
    Centre Leon Berard, Lyon, France Centre Oscar Lambret, Lille, France Institut Bergonié, Bordeaux, France Hôpital de la Timone, Marseille, France Centre Alexis Vautrin, Nancy, France Institut de Cancerologie de la Loire, Saint Etienne, France Institut Paoli Calmette, Marseille, France Centre George François Leclerc, Dijon, France CHU Besançon, Besancon, France PharmaMar, Madrid, Spain
    J Clin Oncol 27:10574. 2009
    ..5mg/m2/CI 24h q21d regimen. The purpose of this study was to assess the outcome of pts treated in this program...
  41. ncbi request reprint Time to secondary resistance (TSR) after interruption of imatinib: Updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival
    F Duffaud
    French Sarcoma Group Hôpital la Timone, Marseille, France Centre Leon Berard, Lyon, France Institut Bergonié, Bordeaux, France Centre Oscar Lambret, Lille, France Centre Alexis Vautrin, Nancy, France Institut Paoli Calmettes, Marseille, France Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:10508. 2009
    ..The impact of IM re-introduction at progression remains unknown regarding the impact of the interruption on the TSR...
  42. ncbi request reprint Consolidation with high-dose chemotherapy for responding patients to standard chemotherapy in advanced, metastatic soft tissue sarcoma (STS): A randomized trial from FNCLCC-French Sarcoma Group
    N N Binh
    PALSAR02 Clinical Trial Group Institut Bergonié, Bordeaux, France Institut Claudius Regaud, Toulouse, France Centre Oscar Lambret, Lille, France Centre Jean Perrin, Clermont Ferrand, France Centre Leon Berard, Lyon, France FNCLCC, Paris, France
    J Clin Oncol 27:10505. 2009
    ..This randomized, open, phase III study was designed to assess whether or not an HD chemotherapy with peripheral blood stem cells (PBSC) would improve OS in patients with advanced or metastatic STS responding to MAID chemotherapy...
  43. ncbi request reprint Malignant gastrointestinal stromal tumors treated with imatinib in France: Results in unselected patients
    A Mathieu-Boue
    Novartis Pharma, Rueil Malmaison, France Hopital Robert Debré, Reims, France Institut Gustave Roussy, Villejuif, France Centre Alexis Vautrin, Nancy, France Hôpital Timone, Marseille, France Hôpital Jean Minjoz, Besancon, France Centre Leon Berard, Lyon, France
    J Clin Oncol 27:e22177. 2009
    ..An observational cohort (EPIGIST) in France was designed to provide data on survival, safety and treatment patterns and quality of life...
  44. ncbi request reprint Outcome of patients with advanced GIST achieving a complete remission (CR) with imatinib (IM) before interruption: Pooled analysis of two consecutive prospective randomizations of the French Sarcoma Group BFR14 phase III trial
    C Chevreau
    Institut Claudius Regaud, Toulouse, France Centre Leon Berard, Lyon, France Institut Bergonié, Bordeaux, France Centre Oscar Lambret, Lille, France Centre Alexis Vautrin, Nancy, France CHU la Timone, Marseille, France Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 27:10549. 2009
    ..IM interruption in responding patients after 1 and 3 yrs of treatment results in a high risk of rapid progression after a few months. The influence of pattern of response on PFS before IM discontinuation is unknown...
  45. pmc Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas
    I Ray Coquard
    , Lyon, France
    Br J Cancer 85:816-22. 2001
    ..In conclusion, poor performance status and lymphopenia identify a subgroup of patients at high risk for early death after chemotherapy...
  46. ncbi request reprint Outcome of 157 adult rhabdomyosarcoma (RMS) patients: A retrospective study from the French Group Sarcoma (GSF-GETO)
    E Bompas
    Centre Rene Gauducheau, Nantes, France Centre René Gauducheau, Saint Herblain, France Institut Bergonié, Bordeaux, France Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France IGR, Villejuif, France Institut Claudius Regaud, Toulouse, France Institut Curie, Paris, France Centre Georges François Leclerc, Dijon, France Medical Oncology, Centre Antoine Lacassagne, Nice, France Centre Alexis Vautrin, Nancy, France CHU, Strasbourg, France Centre François Baclesse, Caen, France Centre Jean Perrin, Clermont Ferrand, France La Timone University Hospital, Marseille, France Centre Paul Papin, Angers, France Centre Leon Berard, Lyon, France
    J Clin Oncol 29:10070. 2011
    ..10070 Background: Five-year overall survival (OS) of localized RMS of children < 18 exceeds 70%, while OS in adult pts is poor. We report a retrospective experience from centers of GSF-GETO...
  47. ncbi request reprint Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: A multivariate analysis of the French Sarcoma Group database
    A Italiano
    French Sarcoma Group GSF GETO Institut Bergonie, Bordeaux, France Institut Gustave Roussy, Villejuif, France Centre René Huguenin, Saint Cloud, France Centre François Baclesse, Caen, France Centre George François Leclerc, Dijon, France Centre Leon Berard, Lyon, France
    J Clin Oncol 27:10504. 2009
    ..We report here the analysis of the impact of AC in the population of STS patients included in the prospective database of the French Sarcoma Group...
  48. ncbi request reprint [High-dose chemotherapy in soft tissue sarcomas of adults]
    I Ray-Coquard
    , 28, rue Laennec, 69008 Lyon
    Bull Cancer 88:858-62. 2001
    ..Phase III studies are required to confirm that survival may be improved by HDCT in subgroups of patients with ASTS...
  49. ncbi request reprint Type of progression in patients treated with imatinib for advanced gastrointestinal stromal tumor (GIST): A study based on the EORTC-ISG-AGITG trial 62005
    M M Van Glabbeke
    EORTC Headquarters, Brussels, Belgium Erasmus University Medical Center, Rotterdam, Netherlands Istituto Nazionale dei Tumori, Milan, Italy Peter MacCallum Cancer Institute, East Melbourne, Australia Institut Gustave Roussy, Villejuif, France HELIOS Klinikum Berlin Buch, Berlin, Germany Klinikum Grosshadern, Muenchen, Germany Royal Marsden Hospital, London, United Kingdom U Z Gasthuisberg, Leuven, Belgium Center Leon Berard, Lyon, France
    J Clin Oncol 27:10536. 2009
    ..We evaluated the impact of progression type and time to first PD (TTP) on survival after progression (SAP) in a randomized phase III trial comparing two doses of imatinib as first line treatment of GIST in 946 patients...
  50. ncbi request reprint Frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis as a surrogate marker for disease management
    J Domont
    Institut Gustave Roussy, Villejuif, France Institut Paoli Calmette, Marseille, France Institut Bergonié, Bordeaux, France Centre Leon Berard, Lyon, France
    J Clin Oncol 27:10501. 2009
    ..As dysregulation of β-catenin (βC) expression hallmarks fibromatosis, herein we searched for βC mutations in a large retrospective European multi-centric tumors series to relate with clinicopathologic parameters...
  51. ncbi request reprint Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib
    A Italiano
    Institut Bergonie, Bordeaux, France Institut Gustave Roussy, Villejuif, France Memorial Sloan Kettering Cancer Center, New York, NY University Hospitals Leuven, Leuven, Belgium Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland La Timone University Hospital, Marseille, France Centre Oscar Lambret, Lille, France Centre Georges François Leclerc, Dijon, France Centre René Gauducheau, Nantes, France Centre Leon Berard, Lyon, France Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy Katholieke Universiteit Leuven, Leuven, Belgium
    J Clin Oncol 29:10044. 2011
    ..10044 Background: Data regarding the management and outcome of metastatic GIST patients (pts) refractory to 1st line imatinib (I) and 2nd sunitinib (S) are limited...
  52. ncbi request reprint Overall survival benefit with masitinib mesylate in imatinib-naive, locally advanced, or metastatic gastrointestinal stromal tumor (GIST): 4-years follow-up of the French Sarcoma Group phase II trial
    J Blay
    Universite Claude Bernard Lyon I, Lyon, France Institut Gustave Roussy, Villejuif, France Institut Bergonié, Bordeaux, France University Hospital Robert Debre, Reims, France Centre Oscar Lambret, Lille, France AB Science, Paris, France APHP CHU Necker, Paris, France
    J Clin Oncol 29:85. 2011
    ..This multicenter phase II study evaluated efficacy and safety of masitinib as a first-line treatment of advanced GIST...
  53. pmc Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome
    T Bachelot
    Centre Leon Berard, Equipe Cytokines et Cancer, INSERM U 590, 28 rue Laennec, 69008 Lyon, France
    Br J Cancer 94:1066-70. 2006
    ..This could have important therapeutic implications with regard to endostatin therapy and raises the question of a possible role of this humoral reaction against endostatin in the neoplastic process...
  54. doi request reprint Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
    H Ghesquieres
    Department of Hematology, Centre Leon Berard, Universite de Lyon, 28 rue Laennec, Lyon, France
    Ann Oncol 21:842-50. 2010
    ..This prospective multicentric phase II study aimed to confirm the results of the C5R protocol of high-dose methotrexate (MTX)-based chemotherapy (CT) for immunocompetent primary central nervous system lymphoma...
  55. ncbi request reprint Sarcomas and malignant phyllodes tumours of the breast--a retrospective study
    C Confavreux
    Centre régional de lutte contre le cancer Léon Bérard, 28 rue Laennec, 69008 Lyon, France
    Eur J Cancer 42:2715-21. 2006
    ..They are composed of a connective tissue stroma and epithelial elements. Pathological presentation ranges from grade I to malignant phyllodes tumours (grade III) where the stromal component clearly exhibits a sarcoma pattern...
  56. pmc Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma
    S Negrier
    Department of Medical Oncology, Centre L BERARD, Lyon, France
    Br J Cancer 65:723-6. 1992
    ..Thus, if age does not seem to modify the potential for response to IL2 therapy, cardiac toxicity appears as a limiting factor for intravenous schedules of IL2...
  57. doi request reprint A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group
    I Ray-Coquard
    Department of Medical Oncology, Léon Bérard Comprehensive Cancer Center, University of Lyon, and EA 4128 SIS Individu Santé, Société, Lyon, France
    Ann Oncol 20:1105-12. 2009
    ....
  58. doi request reprint [Incidence rate, epidemiology of sarcoma and molecular biology. Preliminary results from EMS study in the Rhône-Alpes region]
    F Ducimetière
    Centre Leon Berard, Equipe d évaluation des pratiques médicales, Lyon, France
    Bull Cancer 97:629-41. 2010
    ..Because sarcomas are relatively uncommon yet comprise a wide variety of different entities, second opinion was systematically performed for all included cases...
  59. ncbi request reprint High-dose methotrexate and HELP [Holoxan (ifosfamide), eldesine (vindesine), platinum]--doxorubicin in non-metastatic osteosarcoma of the extremity: a French multicentre pilot study. Fédération Nationale des Centres de Lutte contre le Cancer and Société F
    T Philip
    Centre Leon Berard, Pediatric and Medical Oncology Departement, Lyon, France
    Ann Oncol 10:1065-71. 1999
    ..This study evaluates histological response, long-term outcome, and toxicity in an intensive chemotherapy program given before surgery...
  60. ncbi request reprint Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients
    P Viens
    Department of Oncology, Institut Paoli Calmettes, 232 Blvd Sainte Marguerite, 13273 Marseille Cedex 9, France
    J Clin Oncol 20:24-36. 2002
    ..To evaluate the safety, pharmacokinetics, and efficacy of three different dose levels of pegylated granulocyte colony-stimulating factor (Ro 25-8315) on progenitor cell mobilization and hematologic recovery in cancer patients...
  61. ncbi request reprint Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens
    I Ray-Coquard
    Centre Leon Berard, Lyon, France
    Cancer 82:134-40. 1998
    ..v.) infusion, and vinorelbine (VNB) was delivered at a dose of 6 mg i.v. bolus followed by VNB, 6 mg/m2/day, in continuous i.v. infusion (Days 1-5) every 21 days...
  62. pmc A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients
    T Bachelot
    Département de Cancérologie Médicale Centre Léon Bérard, 28 rue Laennec, 69373 Lyon Cedex, France
    Br J Cancer 87:1079-85. 2002
    ..Three patients were alive, free of disease 30 months after completion of the study. Such therapy allows for high-dose intensity and high cumulative doses on a short period of time with manageable toxicity...
  63. pmc Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
    T Bachelot
    Unité Cytokine et Cancer, INSERM U 453 and Centre Léon Bérard, 28 rue Laënnec 69008 Lyon, France
    Br J Cancer 88:1721-6. 2003
    ..Vascular endothelial growth factor serum and plasma levels are not useful indicators of prognosis for these patients...
  64. ncbi request reprint Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas
    I Ray-Coquard
    Centre Leon Berard, Lyon, France
    Ann Oncol 15:307-15. 2004
    ..The primary management of adult soft tissue sarcomas (STS) is characterized by heterogeneity across centers. Several studies suggest that it is improved when coordinated by specialized sarcoma centers...
  65. ncbi request reprint Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue masses
    I Ray-Coquard
    Centre Leon Berard, 28 rue Laennec, Lyon 69008, France
    Eur J Cancer 39:2021-5. 2003
    ..CNB is accurate, not misleading for s-t-M diagnosis, avoids open biopsy complications, and allows one-surgery or neo-adjuvant chemotherapy planning when combined with appropriate imaging...
  66. doi request reprint Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group
    A Italiano
    Department of Medical Oncology, Institut Bergonie, Bordeaux, France
    Ann Oncol 20:425-30. 2009
    ..There are only scarce data about the benefit of adjunctive chemotherapy in patients with localized synovial sarcoma (SS)...
  67. pmc Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma
    A Ravaud
    Department of Medical Oncology, , Comprehensive Cancer Centre, Bordeaux, France
    Br J Cancer 69:1111-4. 1994
    ..IL-2 and INF-alpha given by this schedule can be safely administered in an outpatient setting. The objective response rate was similar to our previous treatments with high-dose IL-2 given as a continuous infusion...
  68. ncbi request reprint Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients
    K Fizazi
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 16:3736-43. 1998
    ..To assess the outcome and the prognosis of adults with a neoplasm related to the Ewing's sarcoma family of tumors...
  69. ncbi request reprint Updated outcome with long-term follow-up of imatinib for the treatment of progressive or recurrent aggressive fibromatosis (desmoid tumor): A FNCLCC/ French Sarcoma Group phase II trial
    A Dufresne
    Hospital Edouard Herriot, Lyon, France Centre Oscar Lambret, Lille, France Institut Bergonié, Bordeaux, France Institut Gustave Roussy, Villejuif, France Centre Leon Berard, Lyon, France Centre René Huguenin, Saint Cloud, France FNCLCC, Paris, France
    J Clin Oncol 27:10518. 2009
    ..The primary end point was non-progressive disease rate at 3 months. Independent radiological committee reviewed responses. The number of patients was calculated according to a optimal 2-stages design...
  70. ncbi request reprint Prognostic factors in adolescents and young adults (AYA) with high-risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: A study based on two pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials
    B Kasper
    University of Heidelberg, Heidelberg, Germany EORTC Data Centre, Brussels, Belgium Centre Léon Bérard, Lyon, France Tom Baker Cancer Centre, Calgary, AB, Canada Weston Park Hospital, Sheffield, United Kingdom University Hospitals Leuven, Leuven, Belgium
    J Clin Oncol 27:10573. 2009
    ..The aim was to determine prognostic factors for the AYA population...
  71. ncbi request reprint Molecular epidemiology of GISTs: Incidence of PDGFRA and KIT exon 9 mutations in the large French population-based study molecGIST
    J Emile François
    Groupe d Etude des GIST EA4340, Ambroise Pare Hospital, APHP, UVSQ, Boulogne, France Institut Bergonié, Bordeaux, France Institut Paoli Calmettes, Marseille, France Edouard Herriot Hospital, Lyon, France INSERM U590, Centre Leon Berard, Lyon, France CHU, Reims, France Ambroise Paré Hospital, AP HP, Boulogne, France
    J Clin Oncol 27:10535. 2009
    ..The MolecGIST study was design to evaluated prospectively the histological, molecular and clinical characteristics of all GISTs diagnosed at all stages...
  72. ncbi request reprint Association of CD4 lymphopenia with survival in patients with advanced cancer
    J Peron
    Centre Leon Berard, Lyon, France The Royal Marsden Hospital, Sutton, United Kingdom Besançon University Hospital, Besancon, France Centre Leon Berard, Lyon, France
    J Clin Oncol 29:e21145. 2011
    ..We report here the impact of CD4 lyp on patient survival after 10 years...
  73. ncbi request reprint Long-term results of a randomized phase II study of trabectedin by two different dose and schedule regimens in patients with advanced liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide
    G D Demetri
    Dana Farber Cancer Institute, Boston, MA University of Michigan, Ann Arbor, MI Centre Léon Bérard, Lyon, France Sarcoma Oncology Center of Santa Monica, Santa Monica, CA Fox Chase Cancer Center, Philadelphia, PA Istituto Nazionale Tumori, Milan, Italy Tom Baker Cancer Centre, Calgary, AB, Canada Johnson and Johnson, New Brunswick, NJ PharmaMar, Madrid, Spain Institut Gustave Roussy, Paris, France
    J Clin Oncol 27:10509. 2009
    ..v. infusion every week for 3 weeks of a 4-week cycle (qwk 3-h)] in adult patients (pts) with unresectable and/or metastatic liposarcoma or leiomyosarcoma following failure of at least prior anthracycline and ifosfamide chemotherapy...
  74. ncbi request reprint Trends in screening for prostate cancer
    F Eisinger
    Institut Paoli Calmettes, Marseille, France Hôpital Avicenne, Bobigny, France CHU Besançon, Besancon, France Hôpital Edouard Herriot, Lyon, France Clinique de la Porte de Saint Cloud, Boulogne Billancourt, France Capio Clinique du Parc, Toulouse, France Roche, Neuilly sur Seine, France CHRU Trousseau, Tours, France
    J Clin Oncol 27:1542. 2009
    ..1542 Background: Screening for prostate cancer is still in debate. In France, there is no financial barrier for individuals to be screened with the prostate-specific antigen (PSA) test, and there is no recommendation for mass screening...
  75. ncbi request reprint Gastrointestinal stromal tumors (GIST) of the duodenum: A French Sarcoma Group (FSG) retrospective review of 90 patients (pts)
    F Duffaud
    La Timone University Hospital, Marseille, France Centre Leon Berard, Lyon, France Medical Oncology Department, Institut Gustave Roussy, Villejuif, France University Hospital La Timone, Marseille, France Centre Eugène Marquis, Rennes, France University Hospital Robert Debre, Reims, France Centre Jean Perrin, Clermont Ferrand, France Centre Alexis Vautrin, Vandoeuvre les Nancy, France Medical Oncology Department, AP HP, Salpetriere Hospital, University Paris VI, Paris, France Institut Paoli Calmettes, Marseille, France Institut Bergonié, Bordeaux, France Institut de Cancerologie de la Loire, St Priest en Jarez, France CHU, Besancon, France Centre Georges François Leclerc, Dijon, France Centre Oscar Lambret, Lille, France Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 29:10053. 2011
    ..10053 Background: Duodenal GIST (D-GIST) represents ≤ 5% of all GISTs, and clinicopathologic data are reported only from small series. We conducted a retrospective analysis of duodenal GIST over the past 17 years...
  76. ncbi request reprint PALETTE: A randomized, double-blind phase III trial of pazopanib versus placebo in patients with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072)
    W T van der Graaf
    Radboud University Medical Centre, Nijmegen, Netherlands Centre Léon Bérard, Lyon, France Sarcoma Oncology Center, Santa Monica, CA Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea Institut Bergonié, Bordeaux, France Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo, Italy University of Pennsylvania, Philadelphia, PA National Cancer Center Hospital, Tokyo, Japan Institut Gustave Roussy, Villejuif, France Department of Clinical Oncology, Leiden University Medical Center, Leiden, Netherlands The Royal Marsden NHS Foundation Trust, London, United Kingdom Osaka Medical Center, Osaka, Japan European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium EORTC Headquarters, Brussels, Belgium GlaxoSmithKline Oncology, Uxbridge, United Kingdom GlaxoSmithKline, Greenford, United Kingdom Azienda ULSS 9 Treviso, Department of Medicine
    J Clin Oncol 29:LBA10002. 2011
    ....
  77. ncbi request reprint Prognostic factors for progression-free and overall survival in patients with advanced GIST treated with standard-dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group
    F Bertucci
    Institut Paoli Calmettes, Marseille, France Centre Leon Berard, Lyon, France Institut Bergonié, Bordeaux, France Centre Oscar Lambret, Lille, France Centre Alexis Vautrin, Nancy, France La Timone University Hospital, Marseille, France Centre Val d Aurelle, Montpellier, France Institut Claudius Regaud, Toulouse, France Centre René Gauducheau, Nantes, France Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 29:e20506. 2011
    ..e20506 Background: The aim of this work was to investigate factors predicting progression-free survival (PFS) and overall survival (OS) of patients (pts) with advanced GIST treated with 400 mg/day IM included in the BFR14 study...
  78. pmc Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma
    C Bain
    Department of Tumor Biology, , Lyon, France
    Br J Cancer 75:283-6. 1997
    ..008). Thus, these results suggest that, in vivo, IL-2 may enhance cellular-mediated immunity against a tumour antigen and that some MHC molecules are more efficient than others for endogenous tumour antigen presentation...
  79. ncbi request reprint [Soft tissues sarcomas: good medical practices for an optimal management]
    J Fayette
    Service d Oncologie Medicale, Hopital Edouard Herriot, Pavillon E, 5, Place d Arsonval, 69003 Lyon, France
    Cancer Radiother 10:3-6. 2006
    ..Unfortunately, recent studies showed no optimal management for majority of patients treated for sarcomas...
  80. pmc Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes
    C Menetrier-Caux
    Unité Cytokine et Cancer, Centre Leon Berard, Lyon, France
    Br J Cancer 79:119-30. 1999
    ..These results indicate that RCCs induce IL-10, PGE2 and TNF-alpha production by monocytes, which down-regulate the expression of cell-surface molecules involved in antigen presentation as well as their endocytic capacity...
  81. ncbi request reprint [Chemotherapy of sarcomas: optimization of existing drugs and new molecules]
    J Fayette
    Service d Oncologie Medicale, Pavillon E, Hopital Edouard Herriot, Lyon, France
    Cancer Radiother 10:72-7. 2006
    ..Target therapies and antiangiogenic treatment have also begun to show results. It is advisable from now on to distinguish the different sub-type of sarcomas in order to assess cytotoxic activity...
  82. pmc A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region
    P A Cassier
    Department of Medicine, Centre Leon Berard, Lyon, France
    Br J Cancer 103:165-70. 2010
    ..We sought to investigate the molecular epidemiology of sarcomas, including GIST, in the Rhone-Alpes region in France...
  83. ncbi request reprint IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells
    C Menetrier-Caux
    , , , Lyon, France
    Cancer Res 61:3096-104. 2001
    ..Taken together, these results demonstrate that IL-4 and IL-13 reverse the inhibitory effect of tumor cells on DC differentiation...
  84. pmc Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients
    T Philip
    Medical Oncology Department, , Lyon, France
    Br J Cancer 68:1036-42. 1993
    ..This study clearly evidences the selection of the patients receiving immunotherapy and the modification in referrals of a disease induced by a new available therapy. This emphasises the need for prospective studies in this setting...
  85. ncbi request reprint Neoadjuvant MDM2 antagonist RG7112 for well-differentiated and dedifferentiated liposarcomas (WD/DD LPS): A pharmacodynamic (PD) biomarker study
    I L Ray-Coquard
    Centre Leon Berard, Lyon, France Institut Bergonié, Bordeaux, France Institut Gustave Roussy, Villejuif, France Centre Oscar Lambret, Lille, France Hoffmann La Roche, Nutley, NJ Hoffmann La Roche, Penzberg, Germany Roche Diagnostics GmbH, Penzberg, Germany
    J Clin Oncol 29:10007b. 2011
    ..We report a neoadjuvant study of RG7112, a small molecule MDM2 antagonist, in chemotherapy-naive primary or relapsed LPS patients (pts) eligible for tumor resection...
  86. ncbi request reprint Definition of an imatinib trough concentration threshold in the treatment of advanced gastrointestinal stromal tumors (GIST)
    M Molimard
    Groupe Hospitalier Pellegrin, Bordeaux, France Department of Pharmacology Universitary Hospital of Bordeaux, University of Bordeaux, INSERM U657, Bordeaux, France Universite V Segalen Service de Pharmacologie, Bordeaux, France Institut Bergonié, Bordeaux, France Institut Claudius Regaud, Toulouse, France La Timone University Hospital, Marseille, France Centre Alexis Vautrin, Nancy, France Centre Val d Aurelle, Montpellier, France Centre Oscar Lambret, Lille, France Centre Leon Berard, Lyon, France University Hospital Robert Debre, Reims, France Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 29:10013. 2011
    ..We prospectively performed routine analysis of I in advanced GIST pts in which we investigated the relationships between Cmin and progression-free survival (PFS)...
  87. ncbi request reprint Complete response of an HIV negative gastric Kaposi's sarcoma (KS) patient with peritoneal carcinomatosis by liposomal daunorubicin treatment
    A Flechon
    Oncologie Médicale, H pital Edouard Herriot, Lyon, France
    Ann Oncol 12:275-6. 2001
    ..The patient is in complete remission six months after the end of treatment. Liposomal daunorubicin is a promising treatment in the non HIV patient with visceral KS...
  88. ncbi request reprint [Sarcomas of the soft tissues: multidisciplinary approach and new concepts]
    J Fayette
    Hopital Edouard Herriot, Service d Oncologie Medicale, Pavillon E, 5 Place d Arsonval, France
    Rev Med Suisse 1:1979, 1981-4. 2005
  89. ncbi request reprint Treatment of post-transplant lymphomas with anti-B-cell monoclonal antibodies
    Jeanne L Garnier
    Hĵpital Edouard Herriot, Nephrology, Transplantation and Clinical Immunology Department, Lyon, France
    Recent Results Cancer Res 159:113-22. 2002
    ..We must also improve our understanding of the in vivo mechanisms of action of antibody to develop more efficient antibody constructs...
  90. doi request reprint [Targeted treatment of rare connective tissue tumors and sarcomas]
    P Cassier
    Centre Leon Berard, 28, rue Laennec, 69008 Lyon, France, Faculté de médecine Lyon I, Universite de Lyon, Place d Arsonval, Lyon, France
    Bull Cancer 97:693-700. 2010
    ..Translational research is and will be an essential tool for the development of new treatments and the identification of the mechanisms of answer and resistance set up by these tumors...
  91. doi request reprint Influenza vaccination in patients with haematologic malignancies: analysis of practices in 200 patients in a single center
    F Lachenal
    Centre Leon Berard, Department of Haematology, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 97:E33-6. 2010
    ..The aim of this study was to analyse practices and factors influencing vaccination in a single centre, in the light of recent literature data...
  92. ncbi request reprint Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model
    E Jouanneau
    Neurosurgery Department, Neurological and Neurosurgical Hospital Pierre Wertheimer, Claude Bernard University, Lyon, France
    Cancer Immunol Immunother 55:254-67. 2006
    ..These experimental data may be of importance for the design of clinical trials that currently use multiple DC injections...
  93. ncbi request reprint CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer
    Christophe Borg
    INSERM U590, Centre Leon Berard, Lyon, France
    Cancer 101:2675-80. 2004
    ..Lymphopenia is frequently observed in patients with cancer and correlates with the risk of febrile neutropenia and early death after chemotherapy. The phenotype of the depleted lymphocyte populations was investigated in the current study...
  94. ncbi request reprint Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
    Jaap Verweij
    Department of Medical Oncology, Erasmus University Medical Centre, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands
    Lancet 364:1127-34. 2004
    ..Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GIST). We aimed to assess dose dependency of response and progression-free survival with imatinib for metastatic GIST...
  95. ncbi request reprint Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis
    Jacques Olivier Bay
    Centre Jean Perrin, Clermont Ferrand, France
    Int J Cancer 119:706-11. 2006
    ..For the other histological subtypes, the response was not encouraging, but the survival for patients in response or stable suggests further investigation...
  96. ncbi request reprint Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie
    Sylvie Negrier
    Cytokines and Cancer Research Unit, INSERM U 590 and Medical Oncology Department, Cedex 08, France
    J Clin Oncol 22:2371-8. 2004
    ..Our objective was to analyze the prognostic value of circulating vascular endothelial growth factor (VEGF), interleukin-10 (IL-10), and interleukin-6 (IL-6)...
  97. ncbi request reprint Imatinib in patients with metastatic gastrointestinal stromal tumours relapsing after hepatic transplantation
    Emmanuelle Bompas
    Eur J Cancer 40:1456-7. 2004
  98. ncbi request reprint [Gastro-intestinal stromal tumors: news and comments]
    Isabelle Ray-Coquard
    Clinique Mutualiste Eugène André, Lyon, et Centre Léon Bérard, 28, rue Laennec, 69008 Lyon
    Bull Cancer 90:69-76. 2003
    ..Numerous question regarding the integration of this treatment with surgery and the long term outcome of these patients still remain to be answered however...
  99. doi request reprint [Clinical Practice guidelines for the use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin bêta, darbepoetin) in anaemic patients with cancer: 2007 update (summary report)]
    Isabelle Ray-Coquard
    Centre Leon Berard, Lyon
    Bull Cancer 95:433-41. 2008
    ..This article presents a short version of the Recommendations updated in 2007...
  100. ncbi request reprint Gastrointestinal stromal tumors: biology and treatment
    Florence Duffaud
    Service d Oncologie Medicale, CHU Timone Adultes, Marseille, France
    Oncology 65:187-97. 2003
    ..Additional follow-up is necessary. Glivec treatment of GIST is the first example of an efficient targeted treatment in a solid tumor...
  101. ncbi request reprint [Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002]
    Isabelle Ray-Coquard
    INSERM U 453, Centre Leon Berard, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 89:567-9. 2002